Search details
1.
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
J Card Fail
; 28(5): 778-786, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34933097
2.
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Eur Heart J
; 42(6): 684-696, 2021 02 11.
Article
in English
| MEDLINE | ID: mdl-33215209
3.
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Cardiovasc Diabetol
; 20(1): 163, 2021 08 09.
Article
in English
| MEDLINE | ID: mdl-34372849
4.
[Heart failure with preserved left ventricular ejection fraction]. / Herzinsuffizienz mit erhaltener linksventrikulärer Ejektionsfraktion.
Internist (Berl)
; 60(9): 925-942, 2019 Sep.
Article
in German
| MEDLINE | ID: mdl-31432196
5.
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
ESC Heart Fail
; 11(1): 209-218, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37939716
6.
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Eur J Heart Fail
; 2024 Mar 25.
Article
in English
| MEDLINE | ID: mdl-38528728
7.
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.
Heart
; 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38729636
8.
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort.
Eur J Intern Med
; 118: 73-81, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37517939
9.
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Am J Cardiol
; 191: 39-42, 2023 03 15.
Article
in English
| MEDLINE | ID: mdl-36634548
10.
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Eur J Heart Fail
; 25(1): 108-113, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36303266
11.
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Int J Cardiol
; 377: 86-88, 2023 04 15.
Article
in English
| MEDLINE | ID: mdl-36738846
12.
A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Eur J Heart Fail
; 25(8): 1284-1289, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37062878
13.
Evaluation of the HFA-PEFF Score: results from the prospective DIAST-CHF cohort.
ESC Heart Fail
; 9(6): 4120-4128, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36070881
14.
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Eur J Heart Fail
; 24(9): 1559-1568, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35703355
15.
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Eur J Heart Fail
; 24(5): 771-778, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35199421
16.
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Eur Heart J Cardiovasc Pharmacother
; 8(2): 149-156, 2022 02 16.
Article
in English
| MEDLINE | ID: mdl-33822033
17.
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Eur J Heart Fail
; 24(2): 321-331, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34841615
18.
Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
ESC Heart Fail
; 9(6): 4352-4357, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36065795
19.
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.
ESC Heart Fail
; 8(2): 829-841, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33566456
20.
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
JACC Heart Fail
; 9(4): 268-277, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33549556